Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
78 hedge funds and large institutions have $60.2M invested in Navidea Biopharmaceuticals Inc. in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 11 closing their positions.
56% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 81 → 78 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
52% less capital invested
Capital invested by funds: $126M → $60.2M (-$66M)
97% less call options, than puts
Call options by funds: $213K | Put options by funds: $8.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$333K |
| 2 |
Renaissance Technologies
New York
|
+$291K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$195K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$181K |
| 5 |
D.E. Shaw & Co
New York
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Platinum Management
New York
|
-$16.1M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$1.85M |
| 3 |
Jane Street
New York
|
-$713K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$427K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$237K |
NAVB Hedge Fund Activity: Q4 2015 in Review
78 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2015, worth a combined $60.2M — down 52% from $126M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NAVB and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 28 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $333K. The largest seller was Platinum Management, cutting an estimated $16.1M.
- 78 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2015, down from 81 in Q3 2015.
- Funds reported $60.2M of Navidea Biopharmaceuticals Inc. stock for Q4 2015, down 52% quarter-over-quarter.
- 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2015 and 11 closed out, a net change of -3 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2015 was BlackRock Institutional Trust, an estimated $333K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2015 was Platinum Management, an estimated $16.1M sold.
Based on aggregated 13F filings for Q4 2015.